AdnaGen AG is a research and development biotechnology company, based in Langenhagen / Hannover, which is specializing in the development and in marketing of innovative, proprietary products in tumor diagnosis. It is certified according to ISO 9001 and EN 13485 since 2001. AdnaGen has developed test systems, which enable the detection and the characterization of circulating tumor cells (CTC) in the blood of tumor patients. The diagnosis of these tumor cells is thus of great value by offering improved disease monitoring and estimating drug efficacy.
AdnaGen has developed a unique and patented method for the detection and analysis of CTC, which answers hitherto unresolved questions regarding the aftercare of cancer patients. AdnaGen’s tumor diagnostics system offers an overall solution for the detection and analysis of CTC including the enrichment of tumor cells from blood, the analysis of tumor associated gene expression and the stabilization of blood samples for the transport to the laboratory. These test systems serve to improve the early detection of metastases and relapses as compared to currently used test systems.
AdnaGen’s test systems enable furthermore the detection of micrometastasis represented by CTC in the blood circulation long before it would be possible with conventional imaging methods or classical in-vitro diagnostics (IVD), i.e. ELISAs for serum tumor markers.
AdnaGen will be involved in the immunomagnetic isolation of cells and will benchmark the methods.
AdnaGen has developed a unique and patented method for the detection and analysis of CTC, which answers hitherto unresolved questions regarding the aftercare of cancer patients. AdnaGen’s tumor diagnostics system offers an overall solution for the detection and analysis of CTC including the enrichment of tumor cells from blood, the analysis of tumor associated gene expression and the stabilization of blood samples for the transport to the laboratory. These test systems serve to improve the early detection of metastases and relapses as compared to currently used test systems.
AdnaGen’s test systems enable furthermore the detection of micrometastasis represented by CTC in the blood circulation long before it would be possible with conventional imaging methods or classical in-vitro diagnostics (IVD), i.e. ELISAs for serum tumor markers.
AdnaGen will be involved in the immunomagnetic isolation of cells and will benchmark the methods.
